PHILADELPHIA--(BUSINESS WIRE)--Feb. 9, 2006--At the
AmerisourceBergen Corporation (NYSE:ABC) annual meeting of
stockholders, held today in Philadelphia, Company stockholders
re-elected two directors: Richard C. Gozon and J. Lawrence Wilson. In
addition, stockholders approved the amendment to the certificate of
incorporation to increase the number of shares of common stock that
the Company is authorized to issue; approved the amendments to the
Company's 2002 Management Stock Incentive Plan; and ratified the
appointment of Ernst & Young as the Company's independent registered
public accounting firm for the 2006 fiscal year.
During the meeting stockholders also heard a review of the
Company's activities and outlook from Chief Executive Officer, R.
David Yost.
As previously announced, James R. Mellor, Chairman of
AmerisourceBergen's Board of Directors, retired at the conclusion of
today's meeting, and is succeeded by Mr. Gozon.
Mr. Gozon, 67, has been a director of the Company since August
2001. Prior to that, he was a director of AmeriSource Health
Corporation from 1994 to August 2001. He was Executive Vice President
of Weyerhaeuser Company and Chairman of North Pacific Paper Company
from June 1994 until his retirement in 2002. Mr. Gozon is also lead
director of Triumph Group, Inc., a director of UGI Corporation and
AmeriGas Partners, L.P. and a member of the Board of Trustees of
Thomas Jefferson University.
Mr. Wilson, 69, has been a director of the Company since August
2001. Prior to that, he was a director of AmeriSource Health
Corporation from January 2000 to August 2001. He was Chairman and
Chief Executive Officer of Rohm and Haas Company from 1988 until his
retirement in 1999. Mr. Wilson is also a director of Cummins Inc.,
MeadWestvaco Corporation and the Vanguard Group of Investment
Companies.
The AmerisourceBergen Board of Directors is composed of nine
directors.
About AmerisourceBergen
AmerisourceBergen (NYSE:ABC) is one of the world's largest
pharmaceutical services companies serving the United States and
Canada. Servicing both pharmaceutical manufacturers and healthcare
providers in the pharmaceutical supply channel, the Company provides
drug distribution and related services designed to reduce costs and
improve patient outcomes. AmerisourceBergen's service solutions range
from pharmacy automation and pharmaceutical packaging to pharmacy
services for skilled nursing and assisted living facilities,
reimbursement and pharmaceutical consulting services, and physician
education. With more than $54 billion in annual revenue,
AmerisourceBergen is headquartered in Valley Forge, PA, and employs
more than 13,000 people. AmerisourceBergen is ranked #23 on the
Fortune 500 list. For more information, go to
www.amerisourcebergen.com.
Forward-Looking Statements
This news release may contain certain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These statements
are based on management's current expectations and are subject to
uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking
statements. Forward-looking statements may include statements
addressing AmerisourceBergen's future financial and operating results
and the benefits, efficiencies and savings to be derived from the
Company's integration plans to consolidate its distribution network.
The following factors, among others, could cause actual results to
differ materially from those described in any forward-looking
statements: competitive pressures; the loss of one or more key
customer or supplier relationships; customer defaults or insolvencies;
changes in customer mix; supplier defaults or insolvencies; changes in
pharmaceutical manufacturers' pricing and distribution policies or
practices; adverse resolution of any contract or other disputes with
customers (including departments and agencies of the U.S. Government)
or suppliers; regulatory changes; changes in U.S. government policies
(including reimbursement changes arising from the Medicare
Modernization Act); market interest rates; operational or control
issues arising from AmerisourceBergen's outsourcing of information
technology activities; success of the Pharmaceutical Distribution
segment's ability to transition its business model to fee-for-service;
success of integration, restructuring or systems initiatives;
fluctuations in the U.S. dollar - Canadian dollar exchange rate;
economic, business, competitive and/or regulatory developments in
Canada; acquisition of businesses that do not perform as we expect or
that are difficult for us to integrate or control; and other economic,
business, competitive, legal, regulatory and/or operational factors
affecting the business of AmerisourceBergen generally.
More detailed information about these and other risk factors is
set forth in AmerisourceBergen's filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K for
fiscal 2005.
AmerisourceBergen is under no obligation to (and expressly
disclaims any such obligation to) update or alter any forward looking
statements whether as a result of new information, future events or
otherwise.
CONTACT: AmerisourceBergen Corporation, Valley Forge
Michael N. Kilpatric, 610-727-7118
mkilpatric@amerisourcebergen.com
SOURCE: AmerisourceBergen Corporation